About Inside Tx

InsideTX develops the TAMARA nanoparticle formulation system, a microfluidic platform that enables the synthesis of lipidic and polymeric nanoparticles for RNA-LNP therapeutics, facilitating seamless transitions from micro-scale screening to large-scale production. This system addresses the challenges of material waste and scalability in nanoparticle manufacturing, ensuring optimal control over nanoparticle characteristics throughout the drug development process.

```xml <problem> Traditional nanoparticle manufacturing methods often suffer from material waste, scalability issues, and limited control over nanoparticle characteristics, hindering efficient drug development. Transitioning from micro-scale screening to large-scale production can be challenging, requiring significant optimization and adjustments. </problem> <solution> InsideTX offers the TAMARA nanoparticle formulation system, a microfluidic platform designed to streamline the synthesis of lipidic and polymeric nanoparticles for RNA-LNP therapeutics. This system facilitates seamless transitions from micro-scale screening to large-scale production, addressing the challenges of material waste and scalability. The platform provides precise control over nanoparticle characteristics, such as size, polydispersity index (PDI), and encapsulation efficiency (EE), throughout the drug development process. TAMARA enables researchers to work with small volumes, minimizing reagent waste and maximizing yield. The system's reusable chips and integrated cleaning protocol further contribute to cost-effectiveness and ease of use. </solution> <features> - Microfluidic-based nanoparticle formulation system for lipidic and polymeric nanoparticles - Seamless scalability from discovery to in vivo testing, handling volumes from 200 µL to 30 mL - Optimized fluidic design minimizing reagent waste, enabling 100% material use - Precise control over nanoparticle size (50-200 nm), PDI (<0.2), and EE% (>95%) - Reusable microfluidic chips with integrated cleaning protocol - Quick and user-friendly operation, with formulation in under 10 seconds </features> <target_audience> The primary target audience includes researchers and pharmaceutical companies involved in RNA-LNP therapeutics development, particularly those focused on optimizing nanoparticle characteristics and scaling up production. </target_audience> ```

What does Inside Tx do?

Where is Inside Tx located?

Inside Tx is based in Paris, France.

When was Inside Tx founded?

Inside Tx was founded in 2022.

Location

Paris, France

Founded

2022

Employees

14 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Inside Tx

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

insidetx.com 2K+

Founded 2022 – Paris, France

Funding

No funding information available.

Team (10+)

No team information available.

Company Description

Problem

Traditional nanoparticle manufacturing methods often suffer from material waste, scalability issues, and limited control over nanoparticle characteristics, hindering efficient drug development. Transitioning from micro-scale screening to large-scale production can be challenging, requiring significant optimization and adjustments.

Solution

InsideTX offers the TAMARA nanoparticle formulation system, a microfluidic platform designed to streamline the synthesis of lipidic and polymeric nanoparticles for RNA-LNP therapeutics. This system facilitates seamless transitions from micro-scale screening to large-scale production, addressing the challenges of material waste and scalability. The platform provides precise control over nanoparticle characteristics, such as size, polydispersity index (PDI), and encapsulation efficiency (EE), throughout the drug development process. TAMARA enables researchers to work with small volumes, minimizing reagent waste and maximizing yield. The system's reusable chips and integrated cleaning protocol further contribute to cost-effectiveness and ease of use.

Features

Microfluidic-based nanoparticle formulation system for lipidic and polymeric nanoparticles

Seamless scalability from discovery to in vivo testing, handling volumes from 200 µL to 30 mL

Optimized fluidic design minimizing reagent waste, enabling 100% material use

Precise control over nanoparticle size (50-200 nm), PDI (<0.2), and EE% (>95%)

Reusable microfluidic chips with integrated cleaning protocol

Quick and user-friendly operation, with formulation in under 10 seconds

Target Audience

The primary target audience includes researchers and pharmaceutical companies involved in RNA-LNP therapeutics development, particularly those focused on optimizing nanoparticle characteristics and scaling up production.